Related references
Note: Only part of the references are listed.T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
Benedetta Conte et al.
CLINICAL BREAST CANCER (2020)
HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment
Jiayao Li et al.
CELL CYCLE (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
P. S. Blanchette et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Li Chen et al.
NATURE COMMUNICATIONS (2018)
Ado-trastuzumab emtansine (T-DM1) in HER2+advanced breast cancer patients: does pretreatment with pertuzumab matter?
Alessandra Fabi et al.
FUTURE ONCOLOGY (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Prognostic factors in advanced breast cancer: Race and receptor status are significant after development of metastasis
Zhiyong Ren et al.
PATHOLOGY RESEARCH AND PRACTICE (2016)
Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
Heidrun Gevensleben et al.
CLINICAL CANCER RESEARCH (2013)
Genetic heterogeneity and cancer drug resistance
Nicholas C. Turner et al.
LANCET ONCOLOGY (2012)
Detection of HER2 amplification in circulating free DNA in patients with breast cancer
K. Page et al.
BRITISH JOURNAL OF CANCER (2011)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic factors in 1038 women with metastatic breast cancer
R. Largillier et al.
ANNALS OF ONCOLOGY (2008)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
